On August 19, the closing ceremony of the 14th China Innovation and Entrepreneurship Competition (Liaoning Region) was successfully held in Dalian. Liaoning Unicornshell Pharmaceutical Technology Co., Ltd. won the First Prize in the Startup Enterprise Category of the Biomedical Industry Competition for its innovative strength in HPMC pharmaceutical excipients, and was awarded a certificate and trophy. This honor highlights Unicornshell's technological prowess in intelligent manufacturing and the application of green new materials.

Overview of the Competition
The competition, themed "Gather through Innovation, Move Forward Together", was hosted by the Department of Science and Technology of Liaoning Province and organized by the Provincial Science and Technology Innovation Service Center. It attracted numerous innovative enterprises from across the province, providing a platform for exhibition as well as policy and capital support, making it an important bellwether for innovation and entrepreneurship in Liaoning.

Warm Congratulations on the Well‑Deserved Honor
This award is a concentrated reflection of Unicornshell's strengths in R&D capability, technological achievements, and corporate management. Headquartered in Shanghai, Unicornshell focuses on the R&D, production, and sales of HPMC pharmaceutical excipients and innovative traditional Chinese medicine (TCM) formulations, striving to become a leader in the field of intelligent manufacturing of HPMC capsules. Upholding its mission of "promoting medication safety and protecting human health", the company drives the deep integration of intelligent manufacturing and new materials, supporting the upgrading of the pharmaceutical industry and the modernization of TCM.

Core products include hypromellose (HPMC) capsules and hydroxypropyl starch capsules, which combine multiple strategic attributes such as biomedicine, intelligent manufacturing, new materials, and import substitution, aligning with national industrial policies and rural revitalization needs. HPMC capsules represent an important direction for future pharmaceutical excipients, in line with the national "14th Five‑Year Plan" for high‑quality pharmaceutical development and the encouragement policies of the "Industrial Structure Adjustment Guidance Catalog (2019 Edition)". They fundamentally address the safety risks of traditional gelatin capsules and drive the industry toward high‑quality development.

Future Outlook · Global Vision
Unicornshell will continue to adhere to the dual‑driver of "technological innovation + market expansion", deepen industry‑university‑research collaboration, strengthen intellectual property protection, and build an internationally leading HPMC capsule industry system.

In the future, the company will continue to use foreign trade channels as a springboard, focusing on expanding into Southeast Asia, Central Asia, and European markets, forming diversified growth paths. It will follow domestic policies, seize new market opportunities, and deepen cooperation with pharmaceutical companies to promote the application of HPMC capsules in innovative drugs. Through global layout and industrial synergy, Unicornshell strives to become a leader in the HPMC capsule industry and contribute "Chinese momentum" to the high‑quality development of the national biomedical industry.

Innovation Empowers, Strength Crowns
Committed to innovation and living up to expectations: Unicornshell won the championship in the industry category of the Liaoning region with outstanding results. The future holds great promise!